Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice.

Aims: The objective of this study was to assess interindividual variability in plasma trough concentrations of non-nucleoside reverse transcriptase inhibitors (NNRTI) and protease inhibitors (PI) among HIV-infected adults in an outpatient routine clinical practice setting.

Methods: The study included 117 patients who attended our clinic for routine outpatient blood tests and who were receiving antiretroviral therapy which included NNRTI or PI. Patients were not informed that drug concentrations were going to be assessed until blood sampling.

Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.

Background And Objective: To assess the influence of hepatitis C virus (HCV) co-infection and the extent of liver fibrosis on lopinavir/ritonavir pharmacokinetics in HIV-infected patients without liver function impairment.

Methods: Cross-sectional, comparative study enrolling HIV-infected adults receiving lopinavir/ritonavir (400 mg/100 mg twice daily). HIV/HCV co-infected patients were grouped as having advanced fibrosis (HCV+/FIB+, n=7) or not (HCV+/FIB-, n=8) based on the FIB-4 index.

Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice.

Aims: The objective of this study was to assess interindividual variability in trough concentrations of plasma of non-nucleoside reverse transcriptase inhibitors (NNRTI) and protease inhibitors (PI) among HIV-infected adults in a routine outpatient setting.

Methods: One hundred and seventeen patients who attended our clinic for routine blood tests, and who were receiving antiretroviral therapy which included NNRTI or PI were studied. Patients were not informed that drug concentrations were going to be measured until blood sampling.

Reaction of [Fe2(CO)8(mu-CF2)] with AsMe3 and other Lewis bases: syntheses, crystal structures of [Fe(CO)6(AsMe3)2(mu-CF2)] and [Fe(CO)5(AsMe3)3(mu-CF2)], and theoretical considerations.

The difluorcarbene complex [Fe2(CO)8(mu-CF2)] (2) reacts with AsMe3 under CO substitution to give the mu-CF2 containing complexes [Fe2(CO)6(AsMe3)2(mu-CF2)] (4) and [Fe2(CO)5(AsMe3)3(mu-CF2)] (5) which have an [Fe2(CO)9]-like structure as shown by X-ray analyses. In the solid state, 4 forms two isomers, 4a and 4b, in a 3 to 1 ratio, which differ in the position of the mu-CF(2) ligand; 4a has a local C(2) axis and 4b has C1 symmetry. The Fe-Fe distances in 4 and 5 are 2.